CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 22, 2020
Result type: Reports
Project Number: SR0654-000
Product Line: Reimbursement Review

Generic Name: nintedanib

Brand Name: Ofev

Manufacturer: Boehringer Ingelheim (Canada) Ltd.

Therapeutic Area: chronic fibrosing interstitial lung diseases

Indications: Treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD)

Manufacturer Requested Reimbursement Criteria1: As per the Health Canada approved indication for progressive fibrosing-ILD (PF-ILD).

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openJune 25, 2020
Call for patient input closedAugust 17, 2020

- Patient input submission received from British Columbia Lung Association & Lung Groups, Canadian Pulmonary Fibrosis Foundation and The Ontario Lung Association / Lung Health Foundation

Submission receivedJuly 24, 2020
Submission acceptedAugust 13, 2020

- Submission was not accepted for review on 10 Aug 2020

Review initiatedAugust 14, 2020

- Selected for CADTH/INESSS Joint Clinician Engagement

Draft CADTH review report(s) provided to sponsor for commentNovember 10, 2020
Deadline for sponsors commentsNovember 19, 2020
CADTH responses on draft review report(s) provided to sponsorJanuary 08, 2021
Expert committee meeting (initial)January 20, 2021
Draft recommendation issued to sponsorFebruary 01, 2021
February 03, 2021